Amyé Tevaarwerk - Concepedia

Author

Amyé Tevaarwerk

University of Wisconsin Carbone Cancer Center ORCID

Also Known As

A Tevaarwerk, A. J. Tevaarwerk, A. Tevaarwerk, Amye J. Tevaarwerk, Amye J Tevaarwerk, Amye J. Tevaarwerk, Amye Juliet Tevaarwerk, Amye Tevaarwerk, Amyé Tevaarwerk, Mary Terry

231

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

University of Wisconsin Carbone Cancer Center University of Wisconsin–Madison University of Colorado Denver Memorial Sloan Kettering Cancer Center Fox Chase Cancer Center

About

Amyé Tevaarwerk is an author at University of Wisconsin Carbone Cancer Center specializing in oncology, medicine, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	26	1.6K
2	Nursing	13	13	455
3	Health Sciences	4	4	248
4	Education	2	2	180
5	Arts	1	1	33

Amyé Tevaarwerk

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles Lauren M. Zasadil, Kristen A. Andersen, Dabin Yeum, Science Translational Medicine Systems BiologyOncologyChromosome MissegregationPaclitaxel TreatmentBreast Oncology	2014	399
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy Amyé Tevaarwerk, Robert J. Gray, Bryan P. Schneider, Cancer	2012	192
Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Journal of the National Comprehensive Cancer Network Palliative CareSurgical OncologyMedicineCancer ManagementPatient Safety	2018	189
Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Journal of the National Comprehensive Cancer Network Surgical OncologyCancer ManagementGynecologyCancer EducationSocial Sciences	2017	148
Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group Amyé Tevaarwerk, Fengmin Zhao, John H. Fetting, Journal of Clinical Oncology	2014	144
Disparities in Telemedicine Access: A Cross-Sectional Study of a Newly Established Infrastructure during the COVID-19 Pandemic Vivian Hsiao, Thevaa Chandereng, Robin Lankton, Applied Clinical Informatics	2021	141
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131 Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga, Journal of Clinical Oncology	2021	131
Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies Amyé Tevaarwerk, Kyle D. Holen, Dona Alberti, Clinical Cancer Research	2009	124
Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel Christina M. Scribano, Jun Wan, Karla Esbona, Science Translational Medicine	2021	124
A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Seema A. Khan, Fengmin Zhao, Lawrence J. Solin, Journal of Clinical Oncology Metastatic Breast CancerOncologyBreast OncologyBreast Cancer PatientsCancer Management	2020	121

Page 1